TNO-155 is another allosteric SHP2 inhibitor (126) that demonstrated synergistic efficacy with an early-stage compound (82) of adagrasib (i.e., compound 12) in H2122 and H1373 KRAS mutant NSCLC cells (127). Here, KRAS is linked to non-small cell lung carcinoma.